2 active not recruiting, 1 completed, 1 recruiting, 1 unknown. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Unknown 1 |
Follow Hormone Sensitive Prostate Cancer: new trials by email Literature Review of Hormone Sensitive Prostate Cancer trials Research Report on Hormone Sensitive Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Darolutamide, Relugolix - Prostate Cancer, Advanced Prostate Cancer | Phase 2 | Active not recruiting | Atish Choudhury, MD | 33 | 2024-12-13 | 2026-03-09 |
| PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Miami | 34 | 2024-07-03 | 2026-06-16 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Darolutamide, Enzalutamide - Metastatic Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Completed | Alliance Foundation Trials, LLC. | 111 | 2021-08-17 | 2026-09-21 |
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Androgen Deprivation Therapy, Nivolumab, Docetaxel - Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Xiao X. Wei, MD | 47 | 2020-05-11 | 2026-08-12 |
| Cardiovascular Events in GnRH Agonist vs. Antagonist Degarelix, GnRH agonist - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 2 | Unknown | Rabin Medical Center | 80 | 2020-01-17 | 2019-12-02 |
Prostatic Neoplasms (4) · Cardiovascular Diseases (1)
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4)
Androgen Antagonists (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · darolutamide (2) · Docetaxel (1) · Gonadotropin-Releasing Hormone (1) · Goserelin (1) · Leuprolide (1) · Nivolumab (1) · enzalutamide (1) · relugolix (1)
Alliance Foundation Trials, LLC. (1) · Atish Choudhury, MD (1) · Rabin Medical Center (1) · University of Miami (1) · Xiao X. Wei, MD (1)
United States (4) · Israel (1)
Atish Choudhury, MD, PhD (1) · Benjamin J Rich, MD (1) · David Margel, MD, PhD (1) · Evanthia Galanis, MD (1) · Xiao X Wei, MD (1)